Home Cart Sign in  
Chemical Structure| 217087-09-7 Chemical Structure| 217087-09-7

Structure of 217087-09-7

Chemical Structure| 217087-09-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Esomeprazole Magnesium Trihydrate can inhibit the H+/K+ ATPase and reduce acid secretion of gastric parietal cells.

Synonyms: (S)-Omeprazole magnesium trihydrate; (-)-Omeprazole magnesium trihydrate; Esomeprazole magnesium(trihydrate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Esomeprazole magnesium trihydrate

CAS No. :217087-09-7
Formula : C34H42MgN6O9S2
M.W : 767.17
SMILES Code : CC(C=N1)=C(OC)C(C)=C1CS(C2=NC3=C([N-]2)C=C(OC)C=C3)=O.CC(C=N4)=C(OC)C(C)=C4CS(C5=NC6=C([N-]5)C=C(OC)C=C6)=O.[Mg+2].O.O.O
Synonyms :
(S)-Omeprazole magnesium trihydrate; (-)-Omeprazole magnesium trihydrate; Esomeprazole magnesium(trihydrate)
MDL No. :MFCD07698573
InChI Key :VEVZQDGATGBLIC-UHFFFAOYSA-N
Pubchem ID :130565

Safety of Esomeprazole magnesium trihydrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active H+, K+-ATPase inhibitor. Esomeprazole magnesium trihydrate demonstrates promise in the research of upper intestinal disorders and gastroesophageal reflux disease[1].[2].

In Vitro:

Cell Line
Concentration Treated Time Description References
primary human umbilical vein endothelial cells (HUVECs) 100 μmol/L 24 hours Esomeprazole MH reduced sFLT-1 secretion, but MTH had no significant effect Int J Mol Sci. 2022 Aug 23;23(17):9533
primary cytotrophoblast cells 100 μmol/L 24 hours Reduced secretion of sFLT-1 and mRNA expression of sFLT1-e15a and sFLT1-i13 Int J Mol Sci. 2022 Aug 23;23(17):9533

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice L-NAME-induced hypertension model Intraperitoneal injection 10 mg/kg Daily from D7.5 to D17.5 of pregnancy To assess the effect of esomeprazole on L-NAME-induced hypertension model, results showed esomeprazole did not lower blood pressure but enhanced ex vivo acetylcholine-induced vasorelaxation in obese mice. Int J Mol Sci. 2022 Jul 25;23(15):8185
Sprague Dawley (SD) rats Water-immersed and restraint (WIR)-induced stress ulcer model Intraperitoneal injection High dose 50 mg/kg/day, low dose 10 mg/kg/day Once daily for 7 days Esomeprazole pretreatment alleviates WIR-induced stress ulcer damage by inhibiting gastric acid secretion, exerting antioxidant and anti-inflammatory effects, and inactivating the p38 MAPK and NF-κB signaling pathways. Drug Des Devel Ther. 2019 Aug 22;13:2969-2984

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.30mL

0.26mL

0.13mL

6.52mL

1.30mL

0.65mL

13.03mL

2.61mL

1.30mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories